TreatSMA

Cost of SMA care – survey results

A person with SMA impacts the NHS on average £49,723 annually in direct costs, while a loss of productivity per unpaid caregiver costs the society £14,350 each year.

The first results of two surveys commissioned last year by Spinal Muscular Atrophy UK and supported by TreatSMA reveal that the costs resulting from SMA have been understimated to-date. SMA turns out a very expensive disease that costs the society millions of pounds each year.

Below is the first overview of the survey results as published by SMA UK. The results will feed into the debate to what extent treating SMA with Spinraza will be cost-effective for the NHS.

Loader Loading…
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download the document [277.97 KB]

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more